Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Maxime Lagraauw

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Brain, Behavior, and Immunity|August 11, 2015
Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studiesH Maxime Lagraauw, Johan Kuiper, Ilze Bot
The Pediatric Infectious Disease Journal|January 13, 2023
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric PatientsTimothy J Carrothers, H Maxime Lagraauw, Lars Lindbom, et al.
Scientific Reports|February 16, 2019
Stress-induced mast cell activation contributes to atherosclerotic plaque destabilizationH Maxime Lagraauw, Anouk Wezel, Daniël van der Velden, et al.
Journal of Cellular and Molecular Medicine|August 16, 2014
Complement factor C5a induces atherosclerotic plaque disruptionsAnouk Wezel, Margreet R de Vries, H Maxime Lagraauw, et al.
British Journal of Clinical Pharmacology|September 22, 2024
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimenYa-Ping Tu, H Maxime Lagraauw, Michael Method, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metaboliteYa-Ping Tu, Eva Hanze, Fengying Zhu, et al.
Atherosclerosis|June 12, 2015
Mast cells mediate neutrophil recruitment during atherosclerotic plaque progressionAnouk Wezel, H Maxime Lagraauw, Daniël van der Velden, et al.
Atherosclerosis|May 27, 2014
Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activationH Maxime Lagraauw, Marijke M Westra, Martine Bot, et al.
Arthritis Research & Therapy|June 15, 2016
Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profileDaniël van der Velden, H Maxime Lagraauw, Anouk Wezel, et al.
Atherosclerosis|December 9, 2014
RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent mannerAnouk Wezel, Daniël van der Velden, Johanna M Maassen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Brain, Behavior, and Immunity|August 11, 2015
Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studiesH Maxime Lagraauw, Johan Kuiper, Ilze Bot
The Pediatric Infectious Disease Journal|January 13, 2023
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric PatientsTimothy J Carrothers, H Maxime Lagraauw, Lars Lindbom, et al.
Scientific Reports|February 16, 2019
Stress-induced mast cell activation contributes to atherosclerotic plaque destabilizationH Maxime Lagraauw, Anouk Wezel, Daniël van der Velden, et al.
Journal of Cellular and Molecular Medicine|August 16, 2014
Complement factor C5a induces atherosclerotic plaque disruptionsAnouk Wezel, Margreet R de Vries, H Maxime Lagraauw, et al.
British Journal of Clinical Pharmacology|September 22, 2024
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimenYa-Ping Tu, H Maxime Lagraauw, Michael Method, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metaboliteYa-Ping Tu, Eva Hanze, Fengying Zhu, et al.
Atherosclerosis|June 12, 2015
Mast cells mediate neutrophil recruitment during atherosclerotic plaque progressionAnouk Wezel, H Maxime Lagraauw, Daniël van der Velden, et al.
Atherosclerosis|May 27, 2014
Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activationH Maxime Lagraauw, Marijke M Westra, Martine Bot, et al.
Arthritis Research & Therapy|June 15, 2016
Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profileDaniël van der Velden, H Maxime Lagraauw, Anouk Wezel, et al.
Atherosclerosis|December 9, 2014
RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent mannerAnouk Wezel, Daniël van der Velden, Johanna M Maassen, et al.
Pageof 2